How effective is Defibrotide/Defibrotide in the treatment of hepatic veno-occlusive disease?

Defibrotide/Defibrotide (Defibrotide) has been studied and evaluated in clinical trials as a treatment for hepatic veno-occlusive disease (SOS/VOD). Although positive therapeutic effects have been observed in some studies, the efficacy of the drug requires further study and confirmation due to the diversity of clinical trials and differences in disease characteristics.

SOS/VODis a rare but serious liver vascular disease commonly associated with hematopoietic stem cell transplantation such as bone marrow or stem cell transplantation. The pathogenesis of this disease involves damage to capillary endothelial cells, inflammation, and accumulation of fibrin in small blood vessels, which may lead to liver congestion and damage, and in severe cases may lead to multi-organ dysfunction. Defibrotide/Defibrotide sodium is considered to have the potential to alleviate these pathophysiological processes and is expected to improve SOS/VOD clinical symptoms and outcomes.

The following is a review of some clinical experimental data and research results on the effect of Defibrinoside/Defibrotide Sodium in the treatment of SOS/VOD:

1.Clinical Trials in Europe: In Europe, a multicenter, open-label clinical trial studied Defibrososide/DefibrosodiumTreatment of SOS/VOD. The trial included 106 subjects, and the results showed that treatment with Defibrotide/Defibrotide Sodium could significantly reduce patients’ 28-day mortality and improve SOS/VOD clinical symptoms. This study provides preliminary evidence that Defibrotide/Defibrotide Sodium may have the potential to improve survival and clinical outcomes in SOS/VOD patients.

2.Clinical trials in Asia: Some clinical trials have also been conducted in Asia to study the effect of Defibrinoside/Defibrotide Sodium in the treatment of SOS/VOD. A Chinese multicenter study observedDefibrotide/Defibrotide Sodium treatment is effective in patients with SOS/VOD, the results show that, The survival rate of the pan>Defibrotide/Defibrotide Sodium treatment group within 28 days was significantly higher than that of the control group. In addition, some clinical indicators of the Defibrotide/Defibrotide Sodium treatment group, such as liver function indicators and platelet count, also improved.

3.The efficacy of combining other drugs: Some studies have explored the effect of combining Defibrinoside/Defibrotide Sodium with other drugs (such as intravenous gamma globulin, growth factors, etc.) to treat SOS/VOD. These studies suggest that the combination of Defibrotide/Defibrotide Sodium with other medications may further improve efficacy and alleviate SOS/VOD symptoms and complications.

4.Safety and tolerability: In clinical trials, Defibrotide/Defibrotide Sodium is generally considered to be a relatively safe and well-tolerated drug. Although some mild side effects such as nausea, vomiting, headache, etc. may occur, they are usually temporary and can be managed with dose adjustment or symptomatic treatment.

Although there are some clinical trial results supporting the potential of Defibroside/Defibrotide Sodium in the treatment of SOS/VOD, further research is still needed to confirm its long-term efficacy, optimal dosage regimen and dosage. In addition, because the etiology, severity, and patient characteristics of SOS/VOD may differ, the efficacy of Defibrotide/Defibrotide Sodium may vary in different populations.

In summary, Defibrinoside/Defibrotide SodiumAs a drug for the treatment of hepatic veno-occlusive disease, it has shown certain efficacy in clinical trials and may help alleviate the clinical symptoms ofSOS/VOD, improve survival rate, and reduce the risk of complications. However, due to the limited clinical trial data and the fact that the use of drugs is affected by multiple factors, patients should still follow the advice and supervision of their doctors when using defibrotide/defibrotide sodium to ensure the best therapeutic effect. At the same time, further studies are needed in the future to more comprehensively evaluate the efficacy and safety of defibrinoside/defibrotide sodium in the treatment of SOS/VOD.

Defibrinoside/Defibrotide Sodium is not currently on the market in China, so patients cannot purchase it domestically and need to purchase it through foreign purchasing channelsDefibrotide/Defibrotide Sodium. OverseasDefibrinoside/Defibrotide Sodium only has original drugs and no generic drugs. The cheaper original drugs are Turkish original drugs, which cost about 21,000 yuan, which is still very high.